Clinical trials: Immunological Tolerance
Pulmonary Disease, Chronic Obstructive, Airflow Obstruction, Chronic
Non-invasive Ventilation System in Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
When using the Breathe Technologies Ventilation System during simulated activities of daily living (ADLs), Subjects with moderate-to-severe chronic obstructive pulmonary Disease (COPD) will be comfortable and report acceptability.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Airflow Obstruction, Chronic, Chronic Obstructive Airway Disease, Chronic Obstructive Lung Disease
- Trial name
- PRIDE (NCT01355978)
- Testing
- Noninvasive Open Ventilation System
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Breathe Technologies, Inc.
Peripheral Artery Disease, Vascular Function
Impacts of Aquatic vs Land Walking on Vascular Health and Exercise Tolerance in Patients With Peripheral Artery Disease
The purpose of this study was to examine the impacts of a 12-week aquatic walking exercise program on body composition, vascular function, cardiorespiratory capacity, exercise tolerance, muscular strength, and physical function…
- Conditions
- Peripheral Artery Disease, Vascular Function, Exercise Tolerance, Peripheral Arterial Disease
- Trial name
- NCT03849300
- Testing
- Aquatic walking exercise program group 1, Aquatic walking exercise program group 2, Land-based walking exercise group
- Volunteers
- 147 people
- Sponsor
- Pusan National University
Lenses, Intraocular
Tolerance to Residual Astigmatism in Eyes With Vivity®
Low amounts of postoperative residual astigmatism may worsen the visual performance of patients implanted with presbyopia- correcting intraocular lenses (IOLs).
- Trial name
- NCT05392998
- Testing
- Cataract surgery with Vivity intraocular lens implantation
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Clínica Rementería
Breast Cancer
Altering Lipids for Tolerance of Aromatase Inhibitor Therapy
Aromatase inhibitor medications have been approved by the U.S Food and Drug Administration (FDA) for treatment of hormone receptor positive breast cancer.
- Trial name
- ALTA (NCT04268134)
- Testing
- Omega-3 fatty acid supplement
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- University of Michigan Rogel Cancer Center
Rheumatoid Arthritis, Ankylosing Spondylitis
99mTc-rhAnnexin V-128 a Phase I/IIa Study in Patients With Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS)
This was a monocentric, open label, Phase I-IIa study. Eligible patients who signed the ICF received two single intravenous (IV) bolus of the imaging agent 99mTc-rhAnnexin V-128.
- Trial name
- NCT02328027
- Testing
- 99mTc-rhAnnexin V-128
- Where
- Switzerland
- Volunteers
- 16 people
- Sponsor
- Advanced Accelerator Applications
Occupational Exposure
High-Intensity Interval Training to Improve Symptoms of Deployment-Related Respiratory Disease
Some military personnel who have been exposed to burn pit emissions, desert dust, and other airborne hazards experience new respiratory symptoms after deployment.
- Trial name
- NCT05849168
- Testing
- Exercise training
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of Colorado, Denver
Food Hypersensitivity
Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study
Peanut allergy is known to cause severe anaphylactic reactions.The goal of this proposal is to produce a new treatment that would benefit young subjects who have recently been diagnosed with peanut allergy by lowering the risk of…
- Trial name
- DEVIL (NCT00932828)
- Testing
- Peanut oral immunotherapy
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of North Carolina, Chapel Hill
Pre-diabetes
Vitamin D in Minorities With Prediabetes
Vitamin D supplementation in minority subjects with both pre-diabetes and low vitamin D levels will delay the development of diabetes.
- Trial name
- NCT00876928
- Testing
- vitamin D
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- Charles Drew University of Medicine and Science
Metformin Adverse Reaction, Tolerance
Trial of an Intervention to Improve Metformin Persistence and Adherence
Metformin is a safe and effective first-line drug for type 2 diabetes that is also widely recommended for weight loss and diabetes prevention.
- Trial name
- TreatMet (NCT03467763)
- Testing
- Metformin Extended Release Oral Tablet
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Idiopathic Scoliosis, Spondylolisthesis
Low Dose Ketamine Study on Opioid Tolerance and Hyperalgesia
The purpose of this study is to: 1. Establish whether ketamine can decrease opioid consumption and modulate the onset of opioid tolerance and prevent opioid-induced hyperalgesia in pediatric subjects, ages 10 years to 18 years…
- Trial name
- KPSF (NCT01325493)
- Testing
- Ketamine, Normal Saline
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Julia Finkel
Diabetes Mellitus, Non-Insulin-Dependent
The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)
The primary objectives of the ORIGIN study were: To determine whether insulin glargine-mediated normoglycemia can reduce cardiovascular morbidity and/or mortality in people at high risk for vascular disease with either Impaired…
- Trial name
- ORIGIN (NCT00069784)
- Testing
- insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), reusable pen device for insulin injection
- Where
- 40 sites in United States, Argentina and 38 more
- Volunteers
- 12,537 people
- Sponsor
- Sanofi
Epilepsy, Seizures
Vagus Nerve Stimulation Titration Protocol to Improve Tolerance and Accelerate Adaptation
Post-market, on-label, double-blind, randomized, prospective, interventional, tolerability and clinical outcomes study to determine the number of patients achieving their final assigned VNS Therapy dose settings in patients with…
- Trial name
- ASCEND (NCT02385526)
- Testing
- Vagus Nerve Stimulation Therapy
- Where
- 15 sites in United States
- Volunteers
- 67 people
- Sponsor
- Cyberonics, Inc.
Kidney Transplantation, Kidney Disease
Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
Alemtuzumab is a man-made antibody used to treat certain blood disorders. This study will evaluate treatment of kidney transplant recipients with alemtuzumab and other immune system suppressing medications with or without…
- Conditions
- Kidney Transplantation, Kidney Disease, Kidney Failure
- Trial name
- NCT00183248
- Testing
- Alemtuzumab, Mycophenolate mofetil, Sirolimus
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Miami
Diabetes Mellitus, Type 1
A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus
Two forms of insulin lispro (LY900014 and Humalog®) and two forms of insulin aspart (NovoRapid® and Fiasp®) will be given to trial participants with diabetes mellitus type 1 by injection under the skin.
- Trial name
- NCT03449433
- Testing
- LY900014, Insulin Lispro, Insulin Aspart
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
Electrical Stimulation With Different Currents: the Effects on Force, Tolerance and Fatigue in Healthy Subjects
Muscle strength is the amount of force generated by muscle contraction. It could be measured with an isometric dynamometer. This is a validated tool that could be used to measure Maximal Voluntary Isometric Contraction (MVIC) and…
- Trial name
- NCT03340337
- Testing
- Neo-Russian, Aussie, RBS
- Where
- Argentina
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Instituto Universitario de Ciencias de la Salud Fundación H.A. Barceló
Vasculitis, Wegener's Granulomatosis
Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults.
- Conditions
- Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis
- Trial name
- RAVE (NCT00104299)
- Testing
- Azathioprine, Methylprednisolone (or other glucocorticoid), Prednisone
- Where
- 8 sites in United States, Netherlands
- Volunteers
- 197 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cystic Fibrosis
A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)
This study was evaluate the effect of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) on glucose tolerance in CF participants, 12 years of age and older who are heterozygous for the F508del mutation and a minimal function…
- Trial name
- NCT04599465
- Testing
- ELX/TEZ/IVA, IVA
- Where
- 41 sites in Australia, Belgium and 5 more
- Volunteers
- 69 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Psoriasis
A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)
This study will evaluate the efficacy, tolerability, and effect on the quality of life of infliximab in adults with moderate-to-severe psoriasis who are resistant to etanercept after 12 weeks of treatment or have failed 24 weeks…
- Trial name
- TANGO (NCT00686595)
- Testing
- Infliximab
- Volunteers
- 48 people
- Sponsor
- Merck Sharp & Dohme LLC
Pediatric Obesity, Insulin Resistance
Study of Post-meal Blood Sugar Peaks in Association With Vascular Disease in Childhood Obesity
The main purpose of this study is to determine whether treatment with acarbose attenuates post-prandial glycemic excursions in non-diabetic/pre-diabetic obese children as determined by continuous glucose monitoring systems…
- Conditions
- Pediatric Obesity, Insulin Resistance, Impaired Glucose Tolerance, Cardiovascular Disease
- Trial name
- NCT00846521
- Testing
- Acarbose
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Yale University
Advanced Solid Tumor
Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors
The expansion study was a Phase I, multicenter, open label feasibility trial to characterize the pharmacologic activity of IV CPX-POM in bladder tumor tissues obtained from patients with MIBC (Stage ≥T2, N0-N1, M0) who were…
- Trial name
- NCT04608045
- Testing
- CPX-POM
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- CicloMed LLC